如何改善失代偿期肝硬化的护理：慢性病管理干预模式。 - Suppr

Suppr

超能文献

How to improve the care of decompensated cirrhosis: the intervention model for chronic disease management.

作者信息

Kim Beom Kyung

机构信息

Department of Internal medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.

Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Republic of Korea.

出版信息

Hepatobiliary Surg Nutr. 2025 Aug 1;14(4):680-682. doi: 10.21037/hbsn-2025-326. Epub 2025 Jul 23.

DOI:10.21037/hbsn-2025-326

PMID:40893766

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12393109/

Abstract

摘要

相似文献

How to improve the care of decompensated cirrhosis: the intervention model for chronic disease management.如何改善失代偿期肝硬化的护理：慢性病管理干预模式。

Hepatobiliary Surg Nutr. 2025 Aug 1;14(4):680-682. doi: 10.21037/hbsn-2025-326. Epub 2025 Jul 23.

An educational video increases disease-related knowledge in hospitalized patients with decompensated cirrhosis.一部教育视频增加了失代偿期肝硬化住院患者的疾病相关知识。

Can Liver J. 2024 Dec 19;7(4):458-469. doi: 10.3138/canlivj-2024-0037. eCollection 2024 Dec.

A randomized multicenter trial of a chronic disease management intervention for decompensated cirrhosis. The A ustra l ian L iver F a i lur e (ALFIE) trial.一项针对失代偿期肝硬化的慢性病管理干预措施的随机多中心试验。澳大利亚肝脏衰竭（ALFIE）试验。

Hepatology. 2025 Jan 1;81(1):136-151. doi: 10.1097/HEP.0000000000000862. Epub 2024 Mar 27.

Granulocyte colony-stimulating factor with or without stem or progenitor cell or growth factors infusion for people with compensated or decompensated advanced chronic liver disease.粒细胞集落刺激因子联合或不联合干细胞或祖细胞或生长因子输注治疗代偿期或失代偿期晚期慢性肝病患者。

Cochrane Database Syst Rev. 2023 Jun 6;6(6):CD013532. doi: 10.1002/14651858.CD013532.pub2.

Carvedilol vs. propranolol for the prevention of decompensation and mortality in patients with compensated and decompensated cirrhosis.卡维地洛与普萘洛尔预防代偿期和失代偿期肝硬化患者病情恶化及降低死亡率的比较

J Hepatol. 2024 Dec 17. doi: 10.1016/j.jhep.2024.12.017.

[Construction of a machine learning prognostic prediction model based on psoas muscle index for patients with decompensated liver cirrhosis].[基于腰大肌指数构建失代偿期肝硬化患者的机器学习预后预测模型]

Zhonghua Gan Zang Bing Za Zhi. 2025 Jul 20;33(7):667-673. doi: 10.3760/cma.j.cn501113-20231123-00222.

Comparative effectiveness and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in patients with HBV-associated decompensated cirrhosis: insights from a retrospective analysis.替诺福韦艾拉酚胺与替诺福韦酯在乙肝相关失代偿期肝硬化患者中的疗效及安全性比较：一项回顾性分析的见解

BMC Infect Dis. 2025 Aug 19;25(1):1039. doi: 10.1186/s12879-025-11473-6.

Enhancing diagnostic accuracy for HBV-related cirrhosis progression: predictive modeling using combined Golgi protein 73 and α1-microglobulin for the transition from nondecompensated to decompensated cirrhosis.提高乙肝相关肝硬化进展的诊断准确性：使用高尔基体蛋白73和α1-微球蛋白联合进行预测建模以评估非失代偿期肝硬化向失代偿期肝硬化的转变

Eur J Gastroenterol Hepatol. 2025 Aug 1;37(8):961-969. doi: 10.1097/MEG.0000000000002970. Epub 2025 Mar 21.

Evaluating the Impact of Early Palliative Care Consultation on 30-Day and 90-Day Readmissions Among Patients With Decompensated Cirrhosis: A National Perspective.从全国视角评估早期姑息治疗咨询对失代偿期肝硬化患者30天和90天再入院率的影响

J Clin Gastroenterol. 2025 Aug 20. doi: 10.1097/MCG.0000000000002235.

Targeted quantitative lipidomic uncovers lipid biomarkers for predicting the presence of compensated cirrhosis and discriminating decompensated cirrhosis from compensated cirrhosis.靶向定量脂质组学揭示了预测代偿性肝硬化和区分失代偿性肝硬化与代偿性肝硬化的脂质生物标志物。

Clin Chem Lab Med. 2023 Nov 6;62(3):506-521. doi: 10.1515/cclm-2023-0798. Print 2024 Feb 26.

本文引用的文献

Hepatology. 2025 Jan 1;81(1):136-151. doi: 10.1097/HEP.0000000000000862. Epub 2024 Mar 27.

Hepatorenal syndrome: Current concepts and future perspectives.肝肾综合征：当前概念与未来展望。

Clin Mol Hepatol. 2023 Oct;29(4):891-908. doi: 10.3350/cmh.2023.0024. Epub 2023 Apr 13.

Baveno-VII criteria to predict decompensation and initiate non-selective beta-blocker in compensated advanced chronic liver disease patients.贝文诺-七项标准预测代偿期慢性肝病患者失代偿并开始使用非选择性β受体阻滞剂。

Clin Mol Hepatol. 2023 Jan;29(1):135-145. doi: 10.3350/cmh.2022.0181. Epub 2022 Sep 5.

The Quality and Outcomes of Care Provided to Patients with Cirrhosis by Advanced Practice Providers.先进实践提供者为肝硬化患者提供的护理质量和效果。

Hepatology. 2020 Jan;71(1):225-234. doi: 10.1002/hep.30695. Epub 2019 Jun 21.

The 3-month readmission rate remains unacceptably high in a large North American cohort of patients with cirrhosis.在北美一个大型肝硬化患者队列中，3个月再入院率仍然高得令人无法接受。

Hepatology. 2016 Jul;64(1):200-8. doi: 10.1002/hep.28414. Epub 2016 Feb 19.

Efficacy of a chronic disease management model for patients with chronic liver failure.慢性肝衰竭患者慢性病管理模式的疗效。

Clin Gastroenterol Hepatol. 2013 Jul;11(7):850-8.e1-4. doi: 10.1016/j.cgh.2013.01.014. Epub 2013 Jan 29.

ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society.美国心脏病学会/美国心脏协会成人慢性心力衰竭诊断和治疗指南2005年更新版：美国心脏病学会/美国心脏协会实践指南工作组（更新2001年心力衰竭评估和管理指南写作委员会）报告：与美国胸科医师学会及国际心肺移植学会合作制定：得到心律学会认可。

Circulation. 2005 Sep 20;112(12):e154-235. doi: 10.1161/CIRCULATIONAHA.105.167586. Epub 2005 Sep 13.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验